Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome

Phase 4

Recruiting

• Conditions: Turner Syndrome; Hypogonadism; Ovarian; Hormone Replacement Therapy; Estrogen Replacement Therapy; Estrogen Deficiency

• Registration Number: NCT06544473
• Lead Sponsor: Aarhus University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-8-5
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

Inclusion Criteria:<br><br> - Diagnosis of TS regardless of karyotype<br><br> - Age 18-50 years<br><br> - Already receiving estrogen treatment<br><br>Exclusion Criteria:<br><br> - Active systemic chronic diseases<br><br> - Known or suspected breast cancer<br><br> - Known or suspected estradiol-dependent tumors (endometrial cancer or similar)<br><br> - Untreated endometrial hyperplasia<br><br> - Current or previous venous thromboembolism<br><br> - Acute or previous liver disease where liver enzymes are still elevated by a factor 3<br> or more<br><br> - Known hypersensitivity to the medications used<br><br> - Pregnancy

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Equipotency